AstraZeneca plc (ADR) (AZN)
The Company discovers, develops, manufactures and markets prescription pharmaceuticals for important areas of healthcare: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation.
Recs
wooderino
(89.98)
Submitted: 10/27/2009 12:15:49 PM :
Start Price:
$46.37
AZN Score:
-5.54
Showed up on a screen for solid 5 year growth with low debt, cash on hand and still at attractive P/E ratios.
Recs
Hassjo
(98.76)
Submitted: 10/16/2009 2:45:21 PM :
Start Price:
$44.33
AZN Score:
-3.95
Huge demand for FluMist, sales/profits will be massive. Long Term outperform.
Recs
NewlyMinted4Star
(< 20)
Submitted: 10/14/2009 10:30:05 AM :
Start Price:
$44.47
AZN Score:
-0.15
This account tracks the performance of newly minted 4 star stocks - 3 star stocks that recently turned in to 4 star stocks.
Recs
cnj01
(60.84)
Submitted: 9/22/2009 12:03:49 PM :
Start Price:
$46.19
AZN Score:
-5.00
Top notch pharmaceutical
Recs
Recs
shinier
(39.14)
Submitted: 9/4/2009 2:52:54 PM :
Start Price:
$45.35
AZN Score:
+9.02
Looks like a recession stock, and we could be headed out of that sooner than later.
Recs
atsfstan
(36.88)
Submitted: 7/24/2009 11:10:22 AM :
Start Price:
$46.72
AZN Score:
-16.82
10 years of growth and increased profitability. Is maintaining position though an active R&D program. Good cash flow considering stock biy back program (active since early 2001). I like this stock to be an attractive investment for anyone interested in a positon in the medical field.
Recs
cecil97
(< 20)
Submitted: 7/14/2009 10:56:04 PM :
Start Price:
$44.19
AZN Score:
-17.35
H1N1 vaccine demand, low forward P/E, consistent earnings and generous dividend. Next earnings report is 7/30/09
Recs
hartmoney
(< 20)
Submitted: 7/10/2009 10:52:59 AM :
Start Price:
$42.28
AZN Score:
-19.63
MedImmume won the bid to manufacture Swine Flu vaccines. With Obama's recent announcement on government funded program for the same, this could improve AstraZeneca's position.
Recs
TRGoodvsEvil
(< 20)
Submitted: 7/4/2009 12:36:34 AM :
Start Price:
$42.54
AZN Score:
-18.27
2009 World's Most Ethical Companies:
http://ethisphere.com/wme2009/
Recs
knblizzard
(30.16)
Submitted: 6/2/2009 1:07:16 PM :
Start Price:
$41.09
AZN Score:
+7.83
This is a great stock, it will gain with it working with other companies, but it will not out pace the S&P. This is going to be a steady stock with few huge gains.
Recs
RussDavis
(95.21)
Submitted: 5/11/2009 3:21:42 PM :
Start Price:
$37.75
AZN Score:
-2.21
gtrinvestor pick , probably a little late entry on my part since drug test result news and 6% gain today.
Recs
rsfool2000
(87.29)
Submitted: 5/2/2009 8:11:05 PM :
Start Price:
$35.70
AZN Score:
+0.66
1. potential acquisition target
2. solid fundamentals
3. decent dividends
Recs
Chipperfield
(78.92)
Submitted: 4/14/2009 3:33:44 PM :
Start Price:
$34.03
AZN Score:
+0.99
Big Ph. is trading as historically cheap levels.
Recs
mtinvest
(25.47)
Submitted: 4/10/2009 7:24:34 PM :
Start Price:
$33.24
AZN Score:
+4.61
AZN paid too a high price for MedImmune in 2007 (15.2 billion USD for 1.2 billion USD of revenue in 2006 of which more than 1 billion was due to Synagis), but their debt levels are not worrying. AZN has an interesting pipeline and current sales are also very strong. Below is a list of some of the blockbuster drugs of AZN:
Gastrointestinal:
1989 Losec/Prilosec (Omeprazole) - proton pump inhibitor
2000 Nexium (Esomeprazole) - proton pump inhibitor (Omeprazole is just the racemic mixture of esomeprazole and romeprazole, which makes me wonder, how they got this patent and how they manage to charge so much for it)
Neural (schizophrenia, depression):
1997 Seroquel (Quetiapine) - patent expiration in 2011 - dopamine and serotonin receptor antagonist
Cardiovascular:
1992 Seloken/Toprol (Metoprolol) - beta blocker
2000 (2003 in the US) Crestor (Rosuvastatin) - cholesterol drug - competitive inhibitor of HMG-CoA reductase
Respiratory (asthma):
1997 Pulmicort/Rhinocort/Entocort (Budesonide) - patent expiration in 2011/2015 - glucocorticoid steroid
1998 Synagis (Palivizumab) - antibody against Respiratory Syncytial Virus - developed by MedImmune
Recs
englandstumpy
(30.09)
Submitted: 3/30/2009 3:15:12 PM :
Start Price:
$33.76
AZN Score:
-8.24
Crestor looks like a good contributor. Current price depressed.
Recs
G8BigBoom
(69.97)
Submitted: 3/9/2009 6:15:49 PM :
Start Price:
$29.87
AZN Score:
-10.14
Good position to be in.
Recs
Clint35
(65.89)
Submitted: 2/21/2009 10:50:06 PM :
Start Price:
$35.06
AZN Score:
-14.46
They're margins are great. The P/E is low and they raised their dividend not long ago.
Recs
Staka
(98.01)
Submitted: 2/15/2009 4:30:13 AM :
Start Price:
$35.51
AZN Score:
-12.70
Earnings (EQ?)
Recs
kcanant
(99.60)
Submitted: 2/4/2009 2:46:41 PM :
Start Price:
$37.31
AZN Score:
-13.56
Re-load. Div yield 5.1% P/E 16
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 72 1 2 3 4 Next »